BR0316197A - Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro - Google Patents

Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro

Info

Publication number
BR0316197A
BR0316197A BR0316197-8A BR0316197A BR0316197A BR 0316197 A BR0316197 A BR 0316197A BR 0316197 A BR0316197 A BR 0316197A BR 0316197 A BR0316197 A BR 0316197A
Authority
BR
Brazil
Prior art keywords
sepsis
biomarker
patient
onset
profile
Prior art date
Application number
BR0316197-8A
Other languages
English (en)
Inventor
Richard Ivey
Thomas Gentle
Richard Moore
Michael Towns
Nicholas Bachur
Robert Rosenstein
Paul Goldenbaum
Song Shi
Donald Copertino
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of BR0316197A publication Critical patent/BR0316197A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"KIT,PERFIL BIOMARCADOR E MéTODO DE ISOLAR UM BIOMARCADOR DE RESPOSTA DE HOSPEDEIRO". O prognóstico ou diagnóstico prematuros da sépsis leva em conta vantajosamente a intervenção clínica antes que a doença progrida rapidamente além dos estágios iniciais para os estágios mais graves, tais como a sépsis severa ou o choque séptico, que se acham associados com a alta mortalidade. O prognóstico ou diagnóstico prematuros são realizados usando-se uma abordagem de diagnósticos moleculares, envolvendo comparar um perfil de expressão biomarcadora do paciente, com os perfis obtidos de uma ou mais populações de controle, ou de referência, que podem incluir uma população que desenvolva a sépsis. O reconhecimento dos aspectos no perfil biomarcador do paciente, que são característicos do começo da sépsis, permite a um clínico diagnosticar o início da sépsis de um fluido corporal isolado no paciente em um ponto único no tempo. A necessidade de monitorar o paciente durante um período de tempo é, portanto, evitada, vantajosamente possibilitando a intervenção clinica antes do começo dos sintomas sérios da sépsis.
BR0316197-8A 2002-11-12 2003-11-12 Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro BR0316197A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42532202P 2002-11-12 2002-11-12
PCT/US2003/036025 WO2004043236A2 (en) 2002-11-12 2003-11-12 Diagnosis of sepsis or sirs using biomarker profiles

Publications (1)

Publication Number Publication Date
BR0316197A true BR0316197A (pt) 2005-09-27

Family

ID=32312968

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316197-8A BR0316197A (pt) 2002-11-12 2003-11-12 Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro
BR0316223-0A BR0316223A (pt) 2002-11-12 2003-11-12 Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0316223-0A BR0316223A (pt) 2002-11-12 2003-11-12 Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo

Country Status (9)

Country Link
US (2) US7645573B2 (pt)
EP (2) EP1590469A4 (pt)
JP (2) JP2006506070A (pt)
CN (4) CN1742087A (pt)
AU (2) AU2003291488A1 (pt)
BR (2) BR0316197A (pt)
CA (2) CA2505843A1 (pt)
MX (2) MXPA05005071A (pt)
WO (2) WO2004043236A2 (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758503B2 (en) * 1997-01-27 2010-07-20 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20070191697A1 (en) 2006-02-10 2007-08-16 Lynn Lawrence A System and method for SPO2 instability detection and quantification
US20080287756A1 (en) * 1997-07-14 2008-11-20 Lynn Lawrence A Pulse oximetry relational alarm system for early recognition of instability and catastrophic occurrences
US20050060101A1 (en) * 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20060195041A1 (en) 2002-05-17 2006-08-31 Lynn Lawrence A Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US20070093721A1 (en) * 2001-05-17 2007-04-26 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
BR0316232A (pt) 2002-11-12 2005-10-04 Becton Dickinson Co Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo
MXPA05005073A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
CA2505843A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
EP1611255A2 (de) * 2003-04-02 2006-01-04 SIRS-Lab GmbH Verfahren zur erkennung akuter generalisierter entzündlicher zustände (sirs), sepsis, sepsis ähnlichen zuständen und systemischen infektionen
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050164238A1 (en) * 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
DE102004009952B4 (de) * 2004-03-01 2011-06-01 Sirs-Lab Gmbh Verfahren zur Erkennung von Sepsis
DE102004015605B4 (de) * 2004-03-30 2012-04-26 Sirs-Lab Gmbh Verfahren zur Vorhersage des individuellen Krankheitsverlaufs bei Sepsis
JP4441603B2 (ja) * 2004-07-13 2010-03-31 株式会社エヌ・ティ・ティ・データ リスク評価装置、及び、プログラム
DE102004049897B4 (de) * 2004-10-13 2007-11-22 Sirs-Lab Gmbh Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
CN101218355A (zh) * 2004-11-05 2008-07-09 海军秘书处代表的美国政府 利用宿主血液生物基因表达标记诊断和预后判断感染性疾病的临床表型及其它生理状态
GB0426982D0 (en) * 2004-12-09 2005-01-12 Secr Defence Early detection of sepsis
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
FR2881437B1 (fr) 2005-01-31 2010-11-19 Biomerieux Sa Procede pour le diagnostic/pronostic d'un syndrome septique
DE102005013013A1 (de) * 2005-03-21 2006-09-28 Sirs-Lab Gmbh Verwendung von Genaktivitäts-Klassifikatoren für die in vitro Klassifizierung von Genexpressionsprofilen von Patienten mit infektiösem/nichtinfektiösem Multiorganversagen
CA2603550A1 (en) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating neuropsychiatric disorders
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7481280B2 (en) * 2005-06-20 2009-01-27 1243939 Alberta Ltd. Method and apparatus for conducting earth borehole operations using coiled casing
EP2476761A3 (en) * 2005-07-07 2012-10-17 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
US20090197794A1 (en) * 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
BRPI0616720A2 (pt) 2005-09-28 2011-06-28 Becton Dickinson Co método para o diagnóstico ou prognóstico de sepse em um paciente, kit para diagnóstico ou prognóstico, ou monitoração, de sepse em um paciente, e, dispositivo para o diagnóstico ou prognóstico de sepse
AU2006299417A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
WO2007048107A2 (en) * 2005-10-19 2007-04-26 Heska Corporation Proteomic profiling of mast cell tumors and related methods, proteins and nucleic acid molecules
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
ES2349691T3 (es) * 2005-11-25 2011-01-10 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin PROCEDIMIENTO PARA DETECTAR O MONITORIZAR LA SEPTICEMIA ANALIZANDO NIVELES DE EXPRESIÓN DE ARNm DE CITOCINAS.
EP1963527A2 (en) * 2005-12-15 2008-09-03 Becton, Dickinson and Company, Wagner, Jaconda Diagnosis of sepsis
US20070184460A1 (en) * 2006-02-09 2007-08-09 Wei-Mei Ching Diagnostic assay for Orientia tsutsugamushi by detection of responsive gene expression
US20110160075A1 (en) * 2006-02-09 2011-06-30 Wei-Mei Ching Diagnostic assay for orientia tsutsugamushi by detection of responsive gene expression
US7668579B2 (en) * 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
US20080075789A1 (en) * 2006-02-28 2008-03-27 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
US20090220973A1 (en) * 2006-04-03 2009-09-03 Joslin Diabetes Center, Inc. Obesity and body fat distribution
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
GB0610078D0 (en) * 2006-05-20 2006-06-28 Secr Defence Sepsis detection microarray
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CN101743552B (zh) * 2007-07-13 2016-08-10 皇家飞利浦电子股份有限公司 用于急性动态疾病的决策支持系统
US8386184B2 (en) * 2007-08-28 2013-02-26 Becton, Dickinson And Company Systems and methods for determining an amount of starting reagent using the polymerase chain reaction
GB0722582D0 (en) * 2007-11-16 2007-12-27 Secr Defence Early detection of sepsis
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
US7776522B2 (en) * 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
JP2011523357A (ja) * 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
US10943692B1 (en) * 2008-05-07 2021-03-09 Lawrence A. Lynn System and method for generating quaternary images of biologic force propagation and recovery
CA2722773C (en) 2008-05-07 2015-07-21 Lawrence A. Lynn Medical failure pattern search engine
US9458495B2 (en) 2008-07-01 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for assessment of clinical infertility
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
US20120135425A1 (en) * 2010-08-23 2012-05-31 The Ohio State University Research Foundation ELISA for Haptoglobin-Matrix Metalloproteinase 9 Complex as a Diagnostic Test for Conditions Including Acute Inflammation
WO2012122096A2 (en) 2011-03-04 2012-09-13 Sterling Point Research, Llc Systems and methods for optimizing medical care through data monitoring and feedback treatment
US11676730B2 (en) 2011-12-16 2023-06-13 Etiometry Inc. System and methods for transitioning patient care from signal based monitoring to risk based monitoring
US20130231949A1 (en) 2011-12-16 2013-09-05 Dimitar V. Baronov Systems and methods for transitioning patient care from signal-based monitoring to risk-based monitoring
EP2812693B1 (en) 2012-02-07 2017-07-19 Children's Hospital Medical Center A multi-biomarker-based outcome risk stratification model for pediatric septic shock
EP2812705B1 (en) * 2012-02-07 2016-12-21 Children's Hospital Medical Center A multi-biomarker-based outcome risk stratification model for adult septic shock
WO2013123236A1 (en) * 2012-02-14 2013-08-22 Purdue Pharma L.P. Systems and methods to quantify analytes in keratinized samples
EP2834638B1 (en) * 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
US9953453B2 (en) 2012-11-14 2018-04-24 Lawrence A. Lynn System for converting biologic particle density data into dynamic images
US10354429B2 (en) 2012-11-14 2019-07-16 Lawrence A. Lynn Patient storm tracker and visualization processor
US20140241602A1 (en) * 2013-02-28 2014-08-28 Lawrence A. Lynn System for Presentation of Sequential Blood Laboratory Measurements to Image Recognition Systems
AU2014284124B2 (en) 2013-06-20 2020-03-12 Immunexpress Pty Ltd Biomarker identification
EP3074536B1 (en) 2013-11-25 2019-06-19 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
ES2661894T3 (es) * 2013-12-23 2018-04-04 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Procedimiento para detectar una inflamación sistémica y sistema de análisis
JP2017512304A (ja) * 2014-02-06 2017-05-18 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ バイオマーカーシグネチャー法ならびにそのための装置およびキット
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis
GB201406259D0 (en) 2014-04-07 2014-05-21 Univ Edinburgh Molecular predictors of neonatal sepsis
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
US10261068B2 (en) 2015-06-04 2019-04-16 Children's Hospital Medical Center Persevere-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype
PL235777B1 (pl) 2015-07-10 2020-10-19 Univ Jagiellonski Startery, sposób i zestaw diagnostyczny do diagnozowania sepsy
DK3356558T3 (da) 2015-09-30 2022-04-25 Immunexpress Pty Ltd Sirs patogenbiomarkører og anvendelser deraf
DK3371324T3 (da) * 2015-11-06 2021-11-15 Immunexpress Pty Ltd Virusbiomarkører og anvendelser deraf
EP3408773B1 (en) 2016-01-28 2023-09-20 Beckman Coulter, Inc. Infection detection and differentiation systems and methods
GB201605110D0 (en) * 2016-03-24 2016-05-11 Mologic Ltd Detecting sepsis
CN109451744B (zh) 2016-06-26 2022-08-05 斯坦福大学托管董事会 用于危重患者的死亡预后的生物标志物
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
EP3590118A1 (en) 2017-02-28 2020-01-08 Beckman Coulter Inc. Cross discipline disease management system
EP3639276B1 (en) * 2017-06-12 2025-05-07 Koninklijke Philips N.V. Risk assessment of disseminated intravascular coagulation
US11852640B2 (en) 2017-10-27 2023-12-26 Beckman Coulter, Inc. Hematology analyzers and methods of operation
US11644464B2 (en) 2018-04-20 2023-05-09 Beckman Coulter, Inc. Sepsis infection determination systems and methods
US11521706B2 (en) 2018-04-20 2022-12-06 Beckman Coulter, Inc. Testing and representing suspicion of sepsis
US11538566B2 (en) * 2018-05-23 2022-12-27 Beckman Coulter, Inc. Sample analysis with test determination based on identified condition
US11994514B2 (en) 2018-06-15 2024-05-28 Beckman Coulter, Inc. Method of determining sepsis in the presence of blast flagging
CN109022572A (zh) * 2018-09-14 2018-12-18 北京泱深生物信息技术有限公司 作为脓毒症诊断标志物的loc101927627及其应用
CN109022571A (zh) * 2018-09-14 2018-12-18 北京泱深生物信息技术有限公司 Loc105369645作为脓毒症诊断标志物的用途
CN114096845A (zh) 2019-07-12 2022-02-25 贝克曼库尔特有限公司 用于评估对感染的免疫反应的系统和方法
US20210011005A1 (en) * 2019-07-12 2021-01-14 Beckman Coulter, Inc. Systems and methods for evaluating immune response to infection
CN114127861A (zh) 2019-07-12 2022-03-01 贝克曼库尔特有限公司 使用包括收缩压、血液学参数及其组合的生命体征检测败血症的方法
EP3882363A1 (en) * 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP4158352A1 (en) * 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
CN111721941B (zh) * 2020-07-17 2023-08-25 南方科技大学 一种用于判断脓毒症感染情况的装置及其应用
WO2022081786A1 (en) * 2020-10-14 2022-04-21 Lee, Matthew Methods and devices for early diagnosis and monitoring of sepsis
US20250262192A1 (en) * 2021-03-11 2025-08-21 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
CN116304932B (zh) * 2023-05-19 2023-09-05 湖南工商大学 一种样本生成方法、装置、终端设备及介质
CN119064599A (zh) * 2024-09-26 2024-12-03 南昌大学第一附属医院 Nlrc5在制备脓毒症诊断试剂盒中的应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1504597A1 (ru) 1986-06-25 1989-08-30 Актюбинский государственный медицинский институт Способ дифференциальной диагностики сепсиса и локализованной гнойной инфекции у новорожденных
EP0571442A4 (en) 1991-01-14 1995-05-03 Univ New York PROTEIN TSG-14 INDUCED BY CYTOKINE, DNA ENCODING THE PROTEIN AND USES THEREOF.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
RU2072103C1 (ru) 1993-06-10 1997-01-20 Ростовский научно-исследовательский институт акушерства и педиатрии Способ диагностики бактериальных инфекций у новорожденных
US5484705A (en) 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US6190872B1 (en) 1994-05-06 2001-02-20 Gus J. Slotman Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method
US5804370A (en) 1994-06-08 1998-09-08 Critichem Medical Products Limited Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
US6306614B1 (en) 1994-06-08 2001-10-23 Sepsis, Inc. Measurement of analytes in whole blood
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5780237A (en) * 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5708591A (en) 1995-02-14 1998-01-13 Akzo Nobel N.V. Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US6429017B1 (en) * 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US5830679A (en) * 1996-03-01 1998-11-03 New England Medical Center Hospitals, Inc. Diagnostic blood test to identify infants at risk for sepsis
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US6077665A (en) * 1996-05-07 2000-06-20 The Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in neonates
WO1998001738A2 (en) 1996-06-20 1998-01-15 Cornell Research Foundation, Inc. Identification of abnormalities in the expression of t and b cell antigen receptors as disease indicators
US6172220B1 (en) * 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2306501C (en) 1997-10-14 2011-03-29 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
PT1887014E (pt) 1997-10-17 2010-07-05 Genentech Inc Homëlogos de toll humana
US6159683A (en) 1997-12-16 2000-12-12 Spectral Diagnostics, Inc. Method of determining stage of sepsis
ATE239801T1 (de) * 1998-01-22 2003-05-15 Luminex Corp Mikropartikel mit multiplen fluoreszenz-signalen
JP4215397B2 (ja) * 1998-05-14 2009-01-28 ルミネックス コーポレイション 多重分析物診断システム
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
US6312906B1 (en) 1999-01-15 2001-11-06 Imperial College Innovations, Ltd. Immobilized nucleic acid hybridization reagent and method
ES2231167T3 (es) 1999-02-04 2005-05-16 Biomerieux, Inc. Procedimiento y aparato para predecir la disfuncion hemostatica en una muestra de un paciente.
WO2000046404A1 (en) 1999-02-05 2000-08-10 Wrair Walter Reed Army Institute Of Research Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20040225449A1 (en) 1999-06-28 2004-11-11 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using selected gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20050060101A1 (en) 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
DE10027113A1 (de) 1999-12-23 2001-09-27 Andreas Hoeft Verfahren zur Bestimmung von mikrobieller DNS/RNS, Kit dafür und Verwendung des Verfahrens
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
WO2001065257A2 (de) 2000-03-03 2001-09-07 Gerd Schmitz Verfahren zur analyse von exogener und endogener zell-aktivierung
US7363165B2 (en) * 2000-05-04 2008-04-22 The Board Of Trustees Of The Leland Stanford Junior University Significance analysis of microarrays
JP5051960B2 (ja) 2000-06-09 2012-10-17 ビオメリュー・インコーポレイテッド リポタンパク質と急性期タンパク質との複合体を検出し、系の不全または致死のリスクの増加を予測する方法
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US6925389B2 (en) * 2000-07-18 2005-08-02 Correlogic Systems, Inc., Process for discriminating between biological states based on hidden patterns from biological data
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU2002245043B2 (en) 2000-11-16 2006-10-26 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
EP1351702B1 (en) 2000-12-08 2015-03-04 Bioprovar Corporation Trem-1 splice variant for use in modifying immune responses
EP1360336A2 (en) 2001-02-15 2003-11-12 Bayer Corporation Innate immunity markers for rapid diagnosis of infectious diseases
US20040126767A1 (en) 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040121350A1 (en) 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6627607B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
US20020160420A1 (en) 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
EP1270740A1 (en) 2001-06-29 2003-01-02 SIRS-Lab GmbH Biochip and its use for determining inflammation
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
CA2458667A1 (en) 2001-08-30 2003-03-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Educat Ion Of Pennsylvania Method for predicting the outcome of an infection
US20030057106A1 (en) * 2001-09-12 2003-03-27 Zhouxin Shen High throughput chemical analysis by improved desorption/ionization on silicon mass spectrometry
US6939716B2 (en) * 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
DE10155600B4 (de) * 2001-11-09 2009-08-27 Oligene Gmbh Nukleinsäure-Array
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
ATE293794T1 (de) 2001-12-04 2005-05-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von ca 125
ATE272214T1 (de) 2001-12-04 2004-08-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von s100b
DE50104561D1 (de) 2001-12-04 2004-12-23 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
ATE272215T1 (de) 2001-12-04 2004-08-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von ca 19-9
US20040072237A1 (en) 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
US20040038201A1 (en) 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
EP1476752A4 (en) * 2002-02-27 2008-02-13 Bio Merieux Inc METHOD FOR DIAGNOSING AND MONITORING HEMOSTATIC DYSFUNCTION, SEVERE INFECTION AND SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME
US7465555B2 (en) * 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
EP1355158A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker
EP1355159A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis
EP1369693A1 (de) 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Sepsisdiagnose und zur Kontrolle von Spenderblut durch Bestimmung von anti-Asialo-Gangliosid-Antikörpern
US6920721B2 (en) * 2002-06-05 2005-07-26 Adv-Tech Building Systems, Llc Building system
US20040009503A1 (en) 2002-07-03 2004-01-15 Molecular Staging, Inc. Immune modulatory activity of human ribonucleases
EP1523578A1 (en) 2002-07-05 2005-04-20 The University of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
EP1521624A2 (en) 2002-07-11 2005-04-13 Upfront Chromatography A/S An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis
JP5179011B2 (ja) 2002-10-09 2013-04-10 ディーエムアイ バイオサイエンシズ インコーポレイテッド 胎盤虚血および多臓器不全のモニタリング
WO2004043223A2 (en) 2002-11-05 2004-05-27 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
MXPA05005073A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
CA2505843A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
BR0316232A (pt) * 2002-11-12 2005-10-04 Becton Dickinson Co Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo
JP4377375B2 (ja) 2002-12-06 2009-12-02 エフ．ホフマン−ラ ロシュ アーゲー 病原性生物の多重分析検出
EP1426447A1 (en) 2002-12-06 2004-06-09 Roche Diagnostics GmbH Method for the detection of pathogenic gram positive bacteria selected from the genera Staphylococcus, Enterococcus and Streptococcus
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
EP1611255A2 (de) 2003-04-02 2006-01-04 SIRS-Lab GmbH Verfahren zur erkennung akuter generalisierter entzündlicher zustände (sirs), sepsis, sepsis ähnlichen zuständen und systemischen infektionen
FR2855832B1 (fr) 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050164238A1 (en) * 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
SI1882946T1 (sl) 2003-12-23 2010-06-30 Hoffmann La Roche Postopek za ugotavljanje revmatoidnega artritisa z merjenjem anti CCP in interlevkina
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20060024744A1 (en) 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断

Also Published As

Publication number Publication date
MXPA05005072A (es) 2005-07-22
CN1829730A (zh) 2006-09-06
EP1575978A2 (en) 2005-09-21
EP1575978A4 (en) 2006-04-19
EP1590469A2 (en) 2005-11-02
AU2003291484A1 (en) 2004-06-03
US20040106142A1 (en) 2004-06-03
JP2006506069A (ja) 2006-02-23
JP2006506070A (ja) 2006-02-23
BR0316223A (pt) 2005-10-04
EP1590469A4 (en) 2005-12-28
AU2003291488A1 (en) 2004-06-03
CN1738908A (zh) 2006-02-22
WO2004043236A2 (en) 2004-05-27
CA2505785A1 (en) 2004-05-27
US20040097460A1 (en) 2004-05-20
CN1742087A (zh) 2006-03-01
MXPA05005071A (es) 2005-07-22
US7645573B2 (en) 2010-01-12
CA2505843A1 (en) 2004-05-27
WO2004044556A3 (en) 2005-09-09
CN1738909A (zh) 2006-02-22
WO2004044556A2 (en) 2004-05-27
WO2004043236A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
BR0316197A (pt) Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro
BR0316232A (pt) Métodos para determinar o estado de sepsia, para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo
BR0316231A (pt) Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit
DE602008021800C5 (de) Antibiotikum zur Behandlung von lokaler Infektion
Schuurs et al. Time-dependent changes in donor brain death related processes
BR9710500B1 (pt) processo de detecção imunológico de anticorpos, que são dirigidos contra transglutaminase de tecido (ttg) para a diagnose e controle de terapia, bem como agente farmacêutico oral contendo ttg.
DE69911226D1 (de) Prädiktive und therapeutische für nierenerkrankungen gene und proteine
Szyguła-Jurkiewicz et al. Is depression a problem in patients with chronic heart failure
Coraggio et al. Clinical, controlled trial of somatostatin with ranitidine and placebo in the control of peptic hemorrhage of the upper gastrointestinal tract
CN110755443B (zh) 一种表断马钱子苷半缩醛内酯治疗心肌缺血再灌注损伤的用途
EP3710043B1 (en) Fgf10 for the treatment of heart diseases
Mollanoori et al. A novel human T17N-phospholamban variation in idiopathic dilated cardiomyopathy
Sun Infection-related stress phenomenon induced takotsubo cardiomyopathy mimicking ST elevation myocardial infarction
ES2336649T3 (es) Procedimiento de cribado de agentes susceptibles de tratar la obesidad.
Şen et al. Repetitive psychotic episodes induced by rabies vaccine: a case report
Weyand et al. original work is properly cited.
EP1293570A3 (en) Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
AR039967A1 (es) Diagnostico y tratamiento del glaucoma y metodos para descubrir nuevos agentes terapeuticos basandose en la via de senalizacion de wnt/ca2-
CN119662809A (zh) 检测马凡综合征fbn1基因变异位点的多重荧光定量pcr引物、探针及试剂盒
Boyko et al. Changes in Serum Concentration of VEGF Angiogenesis Factor and I-FABP Intestinal Barrier Biomarker in Different Outcomes of Treatment of Patients with Duodenal Injury
RU2225617C1 (ru) Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st
Babushkina et al. Polymorphic CpG-site in the regulatory region of MLH1 in atherosclerosis
Andova et al. A Case of Tacotsubo Cardiomyopathy-How We Uncovered the Diagnosis
Kiberstis Big hearts
ATE420210T1 (de) Diagnose des brustkrebsrisikos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.